Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

AIDS research and human retroviruses - 1 May 2012

Espirito-Santo Maria, Santos-Costa Quirina, Calado Marta, Dorr Patrick, Azevedo-Pereira J Miguel

Abstract excerpt

Human immunodeficiency virus (HIV) entry into susceptible cells involves the interaction between viral envelope glycoproteins with CD4 and a chemokine receptor (coreceptor), namely CCR5 and CXCR4. This interaction has been studied to enable the discovery of a new class of antiretroviral drugs that targets the envelope glycoprotein-coreceptor interaction. However, very few data exist regarding HIV-2 susceptibility...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclohexanes
Share to HIV-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp120

Share to HIV Fusion Inhibitors

Share to Ligands

Share to Receptors, CCR5

Share to Receptors, CXCR4

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 21902586
DOI: 10.1089/AID.2011.0124
PMCID: PMC3332526

Genes

CCR5
CXCR4
CXCL12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.PMID 21902586Read ↗

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Semantic proximity Read ↗

Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140Semantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.Semantic proximity Read ↗

A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4.Semantic proximity Read ↗

Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compoundSemantic proximity Read ↗

Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652Semantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).Semantic proximity Read ↗

A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.Semantic proximity Read ↗

Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner.Semantic proximity Read ↗

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 EntrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.